Sector ratings Abbisko Cayman Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 08:08:19 06/03/2026 GMT			5-day change	1st Jan Change
11.88 ^HKD	+4.76%		-6.53%	-8.69%

03-04	Abbisko Doses First Patient in Tumor Drug Trial	MT
03-03	Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ABBISKO CAYMAN LIMITED	1.02B		-
ARGENX SE	44.16B		AA
WUXI APPTEC CO., LTD.	40.5B		AAA
INSMED INCORPORATED	30.21B	-	BBB	-		-
BIONTECH SE	25.47B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	19.22B		AAA
GENMAB A/S	16.5B		AA
AKESO, INC.	12.64B		B			-
SUMMIT THERAPEUTICS INC.	11.72B	-	-	-		-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	11.51B	-	A	-		-
EXELIXIS, INC.	10.79B		BB
MADRIGAL PHARMACEUTICALS, INC.	9.93B	-	B	-		-
SAMSUNG EPIS HOLDINGS CO., LTD.	9.11B	-	-	-		-	-
IMMUNITYBIO, INC.	8.91B	-	B	-		-
ARROWHEAD PHARMACEUTICALS, INC.	8.38B	-	BBB	-		-
VAXCYTE, INC.	8.53B	-	BBB	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	8.19B	-	-	-	-	-	-	-
PHARMAESSENTIA CORPORATION	8.14B		AA
NUVALENT, INC.	7.82B	-	CCC	-		-
CYTOKINETICS, INCORPORATED	7.44B	-	AA	-		-
Average	15.01B		A
Weighted average by Cap.			A